Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements

Leukemia

Volumn 19, Issue 2, 2005, Pages 214-216

  Lanciotti, Marina ^a   Dufour, C ^a   Corral, L ^b   Di Michele, P ^a   Pigullo, S ^a   De Rossi, G ^c   Basso, G ^d   Leszl, A ^d   Luciani, M ^c   Lo Nigro, L ^e   Micalizzi, C ^a   Valsecchi, M G ^b   Biondi, A ^b   Haupt, R ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

Author keywords

Infant leukemia; MLL gene rearrangement; NQO1 polymorphism

Indexed keywords

MIXED LINEAGE LEUKEMIA PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CELL PROTECTION; CHILD; CHILDHOOD LEUKEMIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; HIGH RISK POPULATION; HUMAN; INFANT; ITALY; KARYOTYPING; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR;

EID: 13544265643     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403613     Document Type: Article

References (20)

1. Pui CH, Kane JR, Crist WM. Biology and treatment of infant leukemia. Leukemia 1995; 9: 762-769.
2. Greaves MF. Infant leukemia biology, aetiology and treatment. Leukemia 1996; 10: 372-377.
3. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000; 96: 24-33.
4. Hunger SP, McGavran L, Meltesen L, Parker NB, Kassenbrock CK, Bitter MA. Oncogenesis in utero: fetal death due to acute myelogenous leukemia with an MLL translocation. Br J Haematol 1998; 103: 539-542.
5. Ford AM, Ridge SA, Cabrera ME, Mahmoud H, Steel CM, Chan LC et al. In utero rearrangements in the trithorax-related oncogene in infants leukemias. Nature 1993; 363: 358-360.
6. Gill Super HJ, Rothberg PG, Kobayashi H, Freeman AI, Diaz MO, Rowley JD. Clonal, non constitutional rearrangements of the MLL gene in infant twins with the acute lymphoblastic leukemia: in utero chromosome rearrangement of 11q23. Blood 1994; 83: 641-644.
7. Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lesson in natural history. Blood 2003; 102: 2321-2333.
8. Greaves M. Aetiology of acute leukemia. Lancet 1997; 349: 344-349.
9. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PU, Ross D et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomicina sensitivity. Cancer Res 1992; 52: 797-802.
10. Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves MF, the United Kingdom Childhood Cancer Study Investigators. A lack of function NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res 1999; 59: 4095-4099.
11. Smith MT, Wang Y, Skibola CF, Slater DJ, Lo Nigro L, Nowell PC et al. Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood 2002; 100: 4590-4593.
12. Eickelmann P, Schulz WA, Rohde D, Schmitz-Drager B, Sies H. Loss of heterozygosity at the NAD(P)H:quinone oxidoreductase locus associated with increased resistance against mitomicina C in a human bladder carcinoma cell line. Biol Chem Hoppe-Seyler 1994; 375 439-445.
13. Gaedigk A, Tyndale RF, Jurima-Romet M, Sellers EM, Grant DM, Leeder JS. NAD(P)H:quinone oxidoreductase polymorphisms and allele frequencies in Caucasian, Chinese, and Canadian Native Indian and Inuit Populations. Pharmacogenetics 1998; 8: 305-313.
14. Ernester L. DT-diaphorase: its structure, function, regulation, and role in antioxidant defence and cancer chemotherapy. In: Yagi K (ed). Pathophysiology of Lipid Peroxides and Related Free Radicals. Basel, Switzerland: S Karger, 1998, pp 149-168.
15. Ross D. Quinone reductases. In: Guengerich FP (ed). Comprehensive Toxicology, Vol. 3. New York, NY: Pergamon Press, 1997, pp 179-197.
16. Asher G, Lotem J, Kama R, Sachs L, Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci USA 2002; 99 3099-3104.
17. Anwar A, Dehn D, Siegel D, Kepa JK, Tang LJ, Pieterpol JA et al. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem 2003; 278: 10368-10373.
18. Cimino G, Rapanotti M, Biondi A, Elia L, Lo Coco F, Price C et al. Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias. Cancer Res 1997; 57: 2879-2883.
19. Blanco JG, Edick MJ, Hancock ML, Winick NJ, Derveux T, Amylon MD et al. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 2002; 12: 605-611.
20. Garte S, Taioli E, Crosti F, Sainati L, Barisone E, Luciani M et al. Deletion of parental GST genes as a possible susceptibility factor in the etiology of infant leukemia. Leukemia Res 2000; 24 971-974.